.
The overall 5 year survival was 50% (95% CI 39-60). Local tumour was the cause of death in 63% of cases and 5 year local control was only 47% (95% CI 36-58) with local recurrence occurring as late as 15 years after treatment. The only favourable independent prognostic factor for survival was the ability to perform surgery (other than biopsy), with or without radiotherapy, as opposed to radiotherapy alone (hazard ratio 0.39; P = 0.003). Only one patient had a biopsy with no further treatment. Favourable independent prognostic factors for local control at 5 years were site (tumours of the head as opposed to the neck, hazard ratio 0.42; P = 0.02) and modality of treatment (combined surgery and radiotherapy compared to either alone, hazard ratio 0.31; P= 0.002). Patients in the combined modality and single treatment modality groups were well balanced for T stage, grade and tumour site. The patients in the combined treatment group had less extensive surgery, yet their local recurrence-free survival was longer.
Unlike soft tissue sarcomas at other sites, those in the head and neck region more often cause death by local recurrence. The addition of radiotherapy to surgery may result in longer local recurrence-free survival.
Soft tissue sarcomas of the head and neck are rare: they comprise <1% of head and neck cancers and <10% of all soft tissue sarcomas (Chang et al., 1991) . There have been few large series and most have included embryonal rhabdomyosarcomas which have a different natural history from other sarcomas and are both radio-and chemosensitive (Pratt, 1969) . We (Robinson et al., 1992) .
The following data were also collected: demographic factors, tumour stage (UICC), predisposing factors, treatment details, and local recurrence plus overall survival. Actuarial plots of survival and local recurrence-free rate, according to the above facors, were compared using log-rank analysis (Peto et al., 1977) . Multivariate Cox regression analysis was carried out to determine the independent prognostic factors for survival and local recurrence (Cox, 1972) . Death was not treated as an event when analysing local recurrence-free rate.
Results
Over 2,500 patients with sarcoma have been treated at the RMH since 1944. Of these, 130 had soft tissue sarcoma of the head and neck (with the exclusions mentioned in the patients' section) which is only 5% of the total. Histological slides from 103 of these patients were available for review (Table I) Twenty-one of these had between 55-66 Gy total dose, six received hypofractionated treatment (6.6 Gy per week) and one had a hyperfractionated regime of 1.25 Gy b.d. to 75.6 Gy in 6 weeks. Lymph nodes were not electively treated. As in extremity sarcomas (Robinson et al., 1990) , treatment was given in two phases, with shrinking fields.
Chemotherapy
Fifteen patients were given chemotherapy. One patient received chemotherapy alone, one after surgery, six after radiotherapy, and seven after both surgery and radiotherapy. Seven patients were given combination chemotherapy. The chemotherapy regimens included methotrexate (nine patients), doxorubicin (seven), vincristine (six), ifosfamide (four) or cyclophosphamide (five).
Survival
The median follow-up was 50 months (range 1-305). Fortyeight patients have died, 46 from sarcoma (Table III) . Local disease was the sole cause of death in 30 (65% of sarcoma deaths), and metastases in 16 (35% of sarcoma deaths). There were no treatment related deaths. Overall actuarial S year survival was 50%. Figure 1 compares the survival of these patients with that of patients with soft tissue sarcoma at all other sites treated at the same institution between 1970 -1990 (Robinson, personal communication, 1992 . The survival of patients with head and neck sarcoma is significantly worse than that seen with such sarcomas at extremity and truncal sites, but is better than for those arising in the retroperitoneum. Five year survival of the 103 patient according to age, site, histology, grade, T stage and treatment are detailed in Table V . The only significant associations with 5 year survival on univariate analysis were age (patients <30 did better than older patients, P<0.05) and treatment (those treated with radiotherapy alone did worse than those treated with surgery ± radiotherapy, P<0.01 Figure 2 ).
Tumour site, histology, T stage and grade did not have any impact on survival in this series.
There were comparatively few events in this study, thus only large differences in prognosis could reliably be detected. For example, with 48 deaths, it would be possible only to reliably detect differences corresponding to a 60% 5 year survival in one group compared with a 30% 5 year survival in another group (P<0.01; 90% power).
The median survival of the patients with neurofibromatosis (Ashby et al., 1986 ). 
(1)
(1) (1)
(1) (1) (1)
(1) was no difference in the time to second local recurrence between different treatment modalities (but numbers are small).
Treatment of local recurrence Fifty patients experienced a local recurrence, of whom 44 received further treatment. Surgery was performed in 29 comprising wide resection in four (14%), complete resection in 19 (66%), and partial resection only in six (20%). It was the sole treatment modality for 17 patients (one wide resection, 15 complete and one partial): six of these patients treated with surgery alone have relapsed locally (35%).
Radiotherapy was given for local recurrence in 19 cases and was the sole treatment modality in ten (20% of local recurrences). Eleven (58%) of the local recurrence group treated with radiotherapy have died of disease, eight from further local recurrence and three from metastases. Six of the patients treated with radiotherapy alone (60%) have died, three from local disease, two from metastasis and one from intercurrent disease.
Surgery and radiotherapy were used together in ten patients who had a local recurrence (the resection was wide -J 0 0.
L.
-i oin three, complete in three and partial in four). Of these ten, five have died of local disease, one has died of metastasis and four are alive without disease.
Chemotherapy was given to 13 patients as part of treatment of local recurrence; in three it was the sole treatment. Eight of the 13 have died, and in all cases death was from local disease.
Treatment of metastasis Twenty-nine patients developed metastatic disease after presentation. Twelve had no treatment. The remainder had treatment involving surgery in five, radiotherapy in four and chemotherapy in eight. Chemotherapy achieved a complete response in one patient and a partial response in another.
Multivariate analysis
Multivariate analysis using the Cox model was performed to determine the significant prognostic factors for survival, failure of local control and disease free survival for the full follow-up period, and at 5 years. Analyses were done for these two time periods because of the protracted follow-up. The results of these analyses are shown in Table VI . The only independent prognostic factor for survival (at both follow-up times) was the use of surgery vs biospy only (hazard ratio 0.39). T stage and grade as prognostic factors did not reach statistical significance. Multivariate analysis for overall disease-free survival only showed age to be a prognostic factor (P = 0.001).
The independent prognostic factors for local recurrence at 5 years were site (Figure 4 At 15 years, the use of radiotherapy remained an independent prognostic factor (P = 0.001); age (P = 0.001) and histology (P = 0.035) also became independent prognostic factors.
Discussion
Soft tissue sarcomas of the head and neck are uncommon and there is only a small number of reported series (Farr et al., 1981; Littman et al., 1983; Wharam et al., 1984; Greager et al., 1985; Fromm et al., 1986; Harmer et al., 1986; Weber et al., 1986; Tsujimoto et al., 1988; Figueiredo et al., 1988; Freedman et al., 1989; Mandard et al., 1989; Rao et al., 1989; Ruka et al., 1989; Frankenthaler et al., 1990 ).
These are summarised in Table VII . When assessing such a series, two potential problems arise. The first is that inclusion of embryonal rhabdomyosarcomas and primary bone sarcomas confuses the overall picture because they have different clinical behaviour. Embryonal rhabdomyosarcomas are very chemosensitive, unlike other soft tissue sarcomas. Fibromatoses should also be excluded because although they may recur locally, they have no metastatic potential and are not regarded as true sarcomas (Enzinger & Weiss, 1988) .
The second point to consider is the change in histological classification that has occurred over the last 50 years (Frankenthaler et al., 1990) . In the past, carcinomas with an extensive desmoplastic reaction were sometimes reported as fibrosarcomas. True fibrosarcomas are now thought to be rare (Fisher, 1990) . Many sarcomas previously classified as fibrosarcoma have been reclassified as malignant fibrous histiocytoma, synovial sarcoma or MPNST following the development of immunohistochemistry and electron microscopy.
This was the case in this series.
There are also differences between the American and British literature in what is included under the classification of soft tissue sarcoma: for example, the American classification would include neuroblastoma and paraganglioma (Farr, 1981; Chang et al., 1991) which in the UK would not be regarded as soft tissue sarcoma. Our series has therefore excluded embryonal rhabdomyosarcoma, neuroblastoma, bone sarcomas and fibromatoses, unlike most of the previously reported series. All tumours analysed in our study had current histological review.
For limb sarcomas, resection is usually defined using the Enneking classification (Simon & Enneking, 1976) which is inappropriate for head and neck tumours because of the difference in anatomical setting. As with sarcomas at other sites, surgical excision of tumours in the head and neck region remains the definitive treatment modality. The extent and adequacy of excision will largely determine survival and the incidence of local recurrence (Enneking, 1983) . Extracapsular enucleation of the tumour will result in up to a 90% local recurrence rate because of the presence of microscopic pseudopodia which tend to grow through the pseudocapsule into the surrounding tissue, and also the presence of 'skip lesions' some distance from the main tumour mass. Wider excision, usually defined in the limb as 5 cm outside the capsule, is associated with a better prognosis, but ideally 'compartmentectomy' should be attempted which results in only a 21 % risk of local recurrence. In the head and neck region, however, wide excision is rarely possible because at presentation, the majority of tumours have extended beyond the confines of their local origin and many lie in close proximity to vital neurovascular structures which cannot be resected safely without risk of severe morbidity. Compartmentectomy has no meaning in the head and neck, and the extent of surgical resection has therefore been redefined as listed in the results so as to be more appropriate to this site.
The overall survival of sarcoma of the head and neck is shorter than that of limb sarcomas which have a 70% 5 year survival (Robinson et al., 1990) and death is more often due to local recurrence. The 5 year local recurrence free survival (47%) is also inferior to that for limb sarcomas. Local recurrence can occur late, even as late as 15 years after treatment. Improvement in local control is therefore of paramount importance in treating sarcomas occurring in the head and neck site.
Although numbers are small, local recurrence either predated or was simultaneous with metastasis. In limb soft tissue sarcomas local recurrence is associated with the development of metastases .
Univariate analysis at 5 years has shown that younger age at diagnosis, and operability are significant prognostic factors for survival. The group treated by radiotherapy alone were inoperable and therefore had a very poor survival (21% at 5 years). Operability is the only significant prognostic variable for survival in the multivariate analysis (P = 0.003).
Multivariate analysis for local control showed that tumours in the neck had a lower local recurrence free survival at 5 (but not at 15) years; P = 0.02. This is not caused by interactions with other factors such as tumour size. Some series suggest the opposite, namely that better local control can be obtained for tumours in the neck (Greager et al., 1985) . Wharam et al. (1984) found that tumours of the neck had a higher risk of local recurrence, although their series consisted predominantly of embryonal rhabdomyosarcoma which was excluded from our series.
Multivariate analysis for local recurrence has shown that at 5 years the use of combined modality treatment (radiotherapy and surgery) is superior to either alone (P = 0.002). This is despite the fact that the combined modality group had less extensive surgery. Obviously this is not a randomised sample, but it would be very difficult to perform a randomised study of combined vs a single modality treatment in such a rare tumour type. The addition of radiotherapy remains an independent prognostic factor for local recurrence-free survival for the length of study follow-up, beyond 5 years (P = 0.001).
In the management of any individual, the risk of local recurrence would have to be weighed against the long term morbidity of giving radiotherapy, especially if the patient were young, the tumour was low grade, and there had been a wide resection according to our criteria. In this series however, wide resection was only possible in 14% of cases. In many patients such clearance is not possible and we would therefore recommend the use of adjuvant radiotherapy for the majority. The majority of our patients received 55-66 Gy using daily fractions of < 2.2 Gy. Within this dose range it would not be possible to show a dose response because of the small numbers involved.
Combined modality treatment with radiotherapy and surgery achieves a higher local recurrence-free survival, although not an improvement in overall survival. However, in the management of head and neck sarcoma, where morbidity and often death result from local recurrence, local control is of paramount importance. This combined approach to treatment should always be considered when managing soft tissue sarcomas at this site where it is vital to obtain local control.
